Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2004 4
2005 3
2006 4
2007 2
2008 4
2009 2
2010 6
2011 6
2012 5
2013 5
2014 1
2016 1
2017 2
2018 3
2019 2
2020 1
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
Tandutinib inhibits the Akt/mTOR signaling pathway to inhibit colon cancer growth.
Ponnurangam S, Standing D, Rangarajan P, Subramaniam D. Ponnurangam S, et al. Mol Cancer Ther. 2013 May;12(5):598-609. doi: 10.1158/1535-7163.MCT-12-0907. Epub 2013 Feb 20. Mol Cancer Ther. 2013. PMID: 23427297 Free PMC article.
We determined the effect of tandutinib on colon cancer growth and identified a mechanism of action. Tandutinib inhibited phosphorylation of c-Kit, Akt, mTOR, and p70S6 kinase. ...
We determined the effect of tandutinib on colon cancer growth and identified a mechanism of action. Tandutinib inhibited phosp …
Tandutinib (MLN518/CT53518) targeted to stem-like cells by inhibiting the function of ATP-binding cassette subfamily G member 2.
Zhao XQ, Dai CL, Ohnuma S, Liang YJ, Deng W, Chen JJ, Zeng MS, Ambudkar SV, Chen ZS, Fu LW. Zhao XQ, et al. Eur J Pharm Sci. 2013 Jun 14;49(3):441-50. doi: 10.1016/j.ejps.2013.04.015. Epub 2013 Apr 22. Eur J Pharm Sci. 2013. PMID: 23619284
Tandutinib is a novel inhibitor of tyrosine kinases FLT3, PDGFR and KIT. ...Importantly, tandutinib selectively sensitized side population cells to mitoxantrone. ...
Tandutinib is a novel inhibitor of tyrosine kinases FLT3, PDGFR and KIT. ...Importantly, tandutinib selectively sensitized sid …
Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications.
Cheng Y, Paz K. Cheng Y, et al. IDrugs. 2008 Jan;11(1):46-56. IDrugs. 2008. PMID: 18175263 Review.
AML is often driven by the overexpression or constitutive activation of receptor tyrosine kinases such as Fms-like tyrosine kinase 3 (FLT3), which serves as a good therapeutic target. Millennium Pharmaceuticals Inc's tandutinib (MLN-518) is an orally active inhibitor of FL …
AML is often driven by the overexpression or constitutive activation of receptor tyrosine kinases such as Fms-like tyrosine kinase 3 (FLT3), …
Neuromuscular junction toxicity with tandutinib induces a myasthenic-like syndrome.
Lehky TJ, Iwamoto FM, Kreisl TN, Floeter MK, Fine HA. Lehky TJ, et al. Neurology. 2011 Jan 18;76(3):236-41. doi: 10.1212/WNL.0b013e3182074a69. Neurology. 2011. PMID: 21242491 Free PMC article.
RESULTS: Six patients were observed to develop a reversible weakness that correlated with the administration of the tandutinib. The onset of weakness after starting tandutinib occurred within 3 to 112 days and in less than 15 days in 3 patients. ...The clinical and …
RESULTS: Six patients were observed to develop a reversible weakness that correlated with the administration of the tandutinib. The o …
A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma.
Odia Y, Sul J, Shih JH, Kreisl TN, Butman JA, Iwamoto FM, Fine HA. Odia Y, et al. CNS Oncol. 2016;5(2):59-67. doi: 10.2217/cns-2015-0010. Epub 2016 Feb 10. CNS Oncol. 2016. PMID: 26860632 Free PMC article. Clinical Trial.
AIM: A Phase II trial of bevacizumab plus tandutinib. METHODS: We enrolled 41 recurrent, bevacizumab-naive glioblastoma patients for a trial of bevacizumab plus tandutinib. ...Tandutinib with bevacizumab was as effective but more toxic than bevacizumab monoth …
AIM: A Phase II trial of bevacizumab plus tandutinib. METHODS: We enrolled 41 recurrent, bevacizumab-naive glioblastoma patients for …
Tandutinib (MLN518) reverses multidrug resistance by inhibiting the efflux activity of the multidrug resistance protein 7 (ABCC10).
Deng W, Dai CL, Chen JJ, Kathawala RJ, Sun YL, Chen HF, Fu LW, Chen ZS. Deng W, et al. Oncol Rep. 2013 Jun;29(6):2479-85. doi: 10.3892/or.2013.2362. Epub 2013 Mar 22. Oncol Rep. 2013. PMID: 23525656 Free PMC article.
Our results revealed that tandutinib significantly enhanced the sensitivity of MRP7-transfected HEK293 cells to the 2 established MRP7 substrates, paclitaxel and vincristine, whereas there was less or no effect on the control vector-transfected HEK293 cells. [3H]-paclitaxe …
Our results revealed that tandutinib significantly enhanced the sensitivity of MRP7-transfected HEK293 cells to the 2 established MRP …
FLT3 inhibitors in acute myeloid leukemia.
Wu M, Li C, Zhu X. Wu M, et al. J Hematol Oncol. 2018 Dec 4;11(1):133. doi: 10.1186/s13045-018-0675-4. J Hematol Oncol. 2018. PMID: 30514344 Free PMC article. Review.
In this review, we summarized the preclinical and clinical studies on new FLT3 inhibitors, including sorafenib, lestaurtinib, sunitinib, tandutinib, quizartinib, midostaurin, gilteritinib, crenolanib, cabozantinib, Sel24-B489, G-749, AMG 925, TTT-3002, and FF-10101. ...
In this review, we summarized the preclinical and clinical studies on new FLT3 inhibitors, including sorafenib, lestaurtinib, sunitinib, …
Preclinical testing of tandutinib in a transgenic medulloblastoma mouse model.
Ohshima-Hosoyama S, Davare MA, Prajapati SI, Abraham J, Lal S, Nelon LD, Kilcoyne A, Giles FJ, Hanes MA, Rubin BP, Keller C. Ohshima-Hosoyama S, et al. J Pediatr Hematol Oncol. 2012 Mar;34(2):116-21. doi: 10.1097/MPH.0b013e3182309fe4. J Pediatr Hematol Oncol. 2012. PMID: 22146535 Free PMC article.
To test our hypothesis, we targeted PDGFR-A mediated tumor growth in vitro and in vivo using the tyrosine kinase inhibitor, tandutinib (MLN-518), which strongly inhibits PDGFR-A. Although PDGFR-A inhibition by this agent resulted in reduced mouse tumor cell growth and incr …
To test our hypothesis, we targeted PDGFR-A mediated tumor growth in vitro and in vivo using the tyrosine kinase inhibitor, tandutinib …
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.
DeAngelo DJ, Stone RM, Heaney ML, Nimer SD, Paquette RL, Klisovic RB, Caligiuri MA, Cooper MR, Lecerf JM, Karol MD, Sheng S, Holford N, Curtin PT, Druker BJ, Heinrich MC. DeAngelo DJ, et al. Blood. 2006 Dec 1;108(12):3674-81. doi: 10.1182/blood-2006-02-005702. Epub 2006 Aug 10. Blood. 2006. PMID: 16902153 Free PMC article. Clinical Trial.
Tandutinib was given orally in doses ranging from 50 mg to 700 mg twice daily The principal dose-limiting toxicity (DLT) of tandutinib was reversible generalized muscular weakness, fatigue, or both, occurring at doses of 525 mg and 700 mg twice daily. ...Western blo …
Tandutinib was given orally in doses ranging from 50 mg to 700 mg twice daily The principal dose-limiting toxicity (DLT) of tandut …
53 results